-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Click on the blue text above to follow us
The researchers say the findings may point the way
to more effective treatments for patients with cancer that do not respond well or recurrent after first-line treatment.
Diffuse large B-cell lymphoma is the most common lymphoma, with 32.
5% of all non-Hodgkin lymphoma patients diagnosed each year in the United States being typed
.
About 30-40% of patients with diffuse large B lymphoma do not respond or relapse
after initial treatment.
Bispecific antibodies can bind to tumor antigens and T cell activation receptors, helping them direct T cells to tumors
.
The bispecific antibody odronextamab has shown promise in activating the T cell response in patients with diffuse large B lymphoma who have not responded to first-line therapy, but many patients still experience relapse
after using this drug.
Wei et al.
have now demonstrated that adding a second bispecific antibody REGN5837 to odronextamab can increase co-stimulatory signals
by bonding to another receptor on T cells.
In collaboration with odronextamab, the addition of REGN5837 enhances antitumor activity
in mice with diffuse large B lymphoma tumors and in laboratory human cells.
In primate testing, this combination also increased T cell activation without showing signs of
toxicity.
Future clinical trials may confirm whether this antibody partner can be a promising non-chemotherapeutic treatment
for diffuse large B-cell lymphoma.
Welcome to pay attention to the official public account of Science, click "Read Original" to visit the original English article, and light up your "like" for medical research
